{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:55:59Z","timestamp":1790600159094,"version":"4.1.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["T005323N"],"award-info":[{"award-number":["T005323N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Accurate detection of M-proteins is essential for diagnosing and monitoring plasma cell dyscrasias. With the advent of highly effective therapies, conventional assays lack sensitivity for low-level M-protein detection and specificity to distinguish M-proteins from therapeutic monoclonal antibodies. Novel mass spectrometry (MS)-based assays may address these limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>This review outlines the clinical utility of MS-based M-protein detection using intact light chain approaches (MALDI-TOF and LC\u2013high-resolution MS) and clonotypic peptide-based methods across multiple myeloma (MM), amyloid light chain (AL) amyloidosis, and other diagnostically challenging entities. A structured literature search was performed (in PubMed\/MEDLINE, Embase, and Web of Science), including studies published through April 2026. Studies were selected using predefined criteria, critically appraised for methodological quality, and narratively synthesized.<\/jats:p>\n                    <jats:p>Across retrospective studies in MM, intact light chain MALDI-TOF MS negativity at treatment milestones was generally associated with improved progression-free survival. Prognostic performance of intact light chain MALDI-TOF MS varied across time points, likely reflecting M-protein elimination kinetics. Compared with intact light chain MALDI-TOF MS, assays measuring bone marrow residual disease often provided superior or complementary prognostic information. Higher-sensitivity (high-resolution\/clonotypic) MS approaches may further improve prognostic stratification, although available data were derived from small cohorts. In AL amyloidosis, MS-based assays detected residual disease beyond complete response criteria, although evidence for prognostic relevance remains preliminary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>MS-based M-protein detection represents a clinically meaningful advancement in plasma cell dyscrasias. Prospective studies with standardized work flows and direct comparison to bone marrow assays and functional imaging are required before full integration into updated response criteria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/clinchem\/hvag127","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:53:39Z","timestamp":1789041219000},"source":"Crossref","is-referenced-by-count":0,"title":["Current Evidence for Integrating Mass Spectrometry into Clinical M-Protein Assessment in Plasma Cell Dyscrasias"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-4023","authenticated-orcid":false,"given":"Louis","family":"Nevejan","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, AZ Sint-Jan Brugge AV , Bruges ,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisiane","family":"Courcelles","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Grand Hospital de Charleroi , Charleroi ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Vercammen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, AZ Sint-Jan Brugge AV , Bruges ,","place":["Belgium"]},{"name":"Observational Clinical Sciences, Vrije Universiteit Brussel , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[{"name":"Division of Haematology, University Hospitals Leuven , Leuven ,","place":["Belgium"]},{"name":"Department of Oncology, Laboratory of Experimental Haematology, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"Department of Laboratory Medicine, University Hospitals Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026092807560224300_hvag127-B1","first-page":"5","article-title":"The paraprotein\u2014an enduring biomarker","volume":"40","author":"Tate","year":"2019","journal-title":"Clin Biochem Rev"},{"key":"2026092807560224300_hvag127-B2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"2026092807560224300_hvag127-B3","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"2026092807560224300_hvag127-B4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"2026092807560224300_hvag127-B5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"2026092807560224300_hvag127-B6","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026092807560224300_hvag127-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"2026092807560224300_hvag127-B8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11912-024-01537-2","article-title":"Minimal residual disease-adapted therapy in multiple myeloma: current evidence and opinions","volume":"26","author":"Meseha","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"2026092807560224300_hvag127-B9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2023020284","article-title":"Potential future direction of measurable residual disease evaluation in multiple myeloma","volume":"142","author":"Mohty","year":"2023","journal-title":"Blood"},{"key":"2026092807560224300_hvag127-B10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10408363.2013.838206","article-title":"Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory","volume":"50","author":"Murray","year":"2013","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2026092807560224300_hvag127-B12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.mayocp.2021.07.024","article-title":"Detection of plasma cell disorders by mass spectrometry: a comprehensive review of 19,523 cases","volume":"97","author":"Dasari","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2026092807560224300_hvag127-B13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clinbiochem.2021.05.012","article-title":"Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins","volume":"95","author":"Campbell","year":"2021","journal-title":"Clin Biochem"},{"key":"2026092807560224300_hvag127-B14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of m-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"key":"2026092807560224300_hvag127-B15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2020.04.002","article-title":"Mass spectrometry\u2013based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma","volume":"22","author":"Martins","year":"2020","journal-title":"J Mol Diagn"},{"key":"2026092807560224300_hvag127-B16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1515\/cclm-2020-0581","article-title":"Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab","volume":"59","author":"Kohlhagen","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2026092807560224300_hvag127-B17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ajh.24772","article-title":"The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic","volume":"92","author":"Milani","year":"2017","journal-title":"Am J Hematol"},{"key":"2026092807560224300_hvag127-B18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","article-title":"A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference","volume":"132","author":"Mills","year":"2018","journal-title":"Blood"},{"key":"2026092807560224300_hvag127-B20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J Proteome Res"},{"key":"2026092807560224300_hvag127-B21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmsacl.2024.02.002","article-title":"Endogenous monoclonal immunoglobulins analyzed using the EXENT\u00ae solution and LC-MS","volume":"32","author":"Barnidge","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"2026092807560224300_hvag127-B22","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.75","article-title":"High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma","volume":"7","author":"Mills","year":"2017","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117634","article-title":"A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma","volume":"552","author":"Muccio","year":"2024","journal-title":"Clin Chim Acta"},{"key":"2026092807560224300_hvag127-B24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-019-0180-1","article-title":"A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis","volume":"9","author":"Sharpley","year":"2019","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1373\/clinchem.2018.299461","article-title":"Direct detection of monoclonal free light chains in serum by use of immunoenrichment-coupled MALDI-TOF mass spectrometry","volume":"65","author":"Sepiashvili","year":"2019","journal-title":"Clin Chem"},{"key":"2026092807560224300_hvag127-B26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-024-00995-y","article-title":"Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry","volume":"14","author":"Giles","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjh.20168","article-title":"Monoclonal immunoglobulin measurement by mass spectrometry in patients with multiple myeloma and kidney failure: analysis from the EuLITE trial","volume":"207","author":"McIlroy","year":"2025","journal-title":"Br J Haematol"},{"key":"2026092807560224300_hvag127-B28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.21037\/atm.2020.03.200","article-title":"How to quantify monoclonal free light chains in plasma cell disorders: which mass spectrometry technology?","volume":"8","author":"Moreau","year":"2020","journal-title":"Ann Transl Med"},{"key":"2026092807560224300_hvag127-B29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/antib13010019","article-title":"Performance characteristics and limitations of the available assays for the detection and quantitation of monoclonal free light chains and new emerging methodologies","volume":"13","author":"Giles","year":"2024","journal-title":"Antibodies"},{"key":"2026092807560224300_hvag127-B30","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/clinchem\/hvae130","article-title":"Clonality determination by detecting unmodified monoclonal serum free light chains using on-probe extraction coupled with liquid chromatography-high-resolution mass spectrometry","volume":"70","author":"Yeung","year":"2024","journal-title":"Clin Chem"},{"key":"2026092807560224300_hvag127-B31","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1515\/cclm-2015-0917","article-title":"Monitoring free light chains in serum using mass spectrometry","volume":"54","author":"Barnidge","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2026092807560224300_hvag127-B32","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"},{"key":"2026092807560224300_hvag127-B33","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)","volume":"30","author":"Fan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026092807560224300_hvag127-B34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/clinchem\/hvab017","article-title":"Clonotypic features of rearranged immunoglobulin genes yield personalized biomarkers for minimal residual disease monitoring in multiple myeloma","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"},{"key":"2026092807560224300_hvag127-B35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.HS9.0000936168.61107.6f","article-title":"P10 an ultra-sensitive method for sequencing and monitoring of M-protein in peripheral blood (M-insight)","volume":"7","author":"Bonifay","year":"2023","journal-title":"HemaSphere"},{"key":"2026092807560224300_hvag127-B36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin Chem"},{"key":"2026092807560224300_hvag127-B37","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/clinchem\/hvae179","article-title":"Applications of mass spectrometry proteomic methods to immunoglobulins in the clinical laboratory","volume":"70","author":"Murray","year":"2024","journal-title":"Clin Chem"},{"key":"2026092807560224300_hvag127-B38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/10408363.2023.2209652","article-title":"Advances in minimal residual disease monitoring in multiple myeloma","volume":"60","author":"Wijnands","year":"2023","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2026092807560224300_hvag127-B39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjh.18226","article-title":"The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: where are we now and which questions remain unanswered?","volume":"198","author":"Giles","year":"2022","journal-title":"Br J Haematol"},{"key":"2026092807560224300_hvag127-B40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cll.2021.03.003","article-title":"Clinical mass spectrometry approaches to myeloma and amyloidosis","volume":"41","author":"Murray","year":"2021","journal-title":"Clin Lab Med"},{"key":"2026092807560224300_hvag127-B41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.17195","article-title":"Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma","volume":"193","author":"Abeykoon","year":"2021","journal-title":"Br J Haematol"},{"key":"2026092807560224300_hvag127-B42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702\/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B44","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma","volume":"6","author":"Puig","year":"2022","journal-title":"Blood Adv"},{"key":"2026092807560224300_hvag127-B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-022-01779-8","article-title":"Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment","volume":"37","author":"Claveau","year":"2023","journal-title":"Leukemia"},{"key":"2026092807560224300_hvag127-B47","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry-based assessment of m protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"key":"2026092807560224300_hvag127-B48","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.3324\/haematol.2024.285742","article-title":"Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial","volume":"109","author":"Puig","year":"2024","journal-title":"Haematologica"},{"key":"2026092807560224300_hvag127-B49","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"key":"2026092807560224300_hvag127-B50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-024-01045-3","article-title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.24.00635","article-title":"Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma","volume":"43","author":"Lasa","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092807560224300_hvag127-B52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100124","article-title":"Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma","volume":"2","author":"Kubicki","year":"2025","journal-title":"Blood Neoplasia"},{"key":"2026092807560224300_hvag127-B53","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A personalized mass spectrometry\u2013based assay to monitor m-protein in patients with multiple myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026092807560224300_hvag127-B54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-023-00803-z","article-title":"Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B55","first-page":"764","article-title":"Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma","volume":"110","author":"Zhao","year":"2025","journal-title":"Haematologica"},{"key":"2026092807560224300_hvag127-B56","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1016\/j.clml.2025.04.017","article-title":"Blood-based measurable residual disease by clonotypic mass spectrometry is prognostic in patients with multiple myeloma undergoing autologous hematopoietic cell transplant","volume":"25","author":"Slade","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026092807560224300_hvag127-B57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/pharmaceutics17010135","article-title":"Monitoring M-protein, therapeutic antibodies, and polyclonal antibodies in a multiparametric mass spectrometry assay provides insight into therapy response kinetics in patients with multiple myeloma","volume":"17","author":"Wijnands","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026092807560224300_hvag127-B58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41571-025-01017-x","article-title":"Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma","volume":"22","author":"Paiva","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092807560224300_hvag127-B59","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1515\/cclm-2025-1056","article-title":"Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish society of laboratory medicine and the Spanish society of hematology and hemotherapy. Part III: clinical and analytical recommendations for the study of monoclonal gammopathies by MALDI-TOF mass spectrometry","volume":"64","author":"Agull\u00f3","year":"2026","journal-title":"Clin Chem Lab Med"},{"key":"2026092807560224300_hvag127-B60","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1515\/cclm-2025-0894","article-title":"Extended verification of an automated MALDI-TOF mass spectrometry system for high throughput serum M-protein measurement","volume":"64","author":"Nevejan","year":"2025","journal-title":"Clin Chem Lab Med"},{"key":"2026092807560224300_hvag127-B61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am J Hematol"},{"key":"2026092807560224300_hvag127-B62","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"},{"key":"2026092807560224300_hvag127-B63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026092807560224300_hvag127-B64","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/hematology.2020000122","article-title":"Monoclonal gammopathies of clinical significance","volume":"2020","author":"Dispenzieri","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2026092807560224300_hvag127-B65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"key":"2026092807560224300_hvag127-B66","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ajh.26240","article-title":"POEMS syndrome: 2021 update on diagnosis, risk-stratification, and management","volume":"96","author":"Dispenzieri","year":"2021","journal-title":"Am J Hematol"},{"key":"2026092807560224300_hvag127-B67","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026092807560224300_hvag127-B68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.12703\/r\/11-34","article-title":"Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond","volume":"11","author":"Abeykoon","year":"2022","journal-title":"Fac Rev"},{"key":"2026092807560224300_hvag127-B69","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","article-title":"N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression","volume":"34","author":"Dispenzieri","year":"2020","journal-title":"Leukemia"},{"key":"2026092807560224300_hvag127-B70","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061153","article-title":"Mass spectrometry as alternative method to identify and monitor non-secretory progressive disease in patients with multiple myeloma","volume":"12","author":"Agull\u00f3","year":"2024","journal-title":"Biomedicines"},{"key":"2026092807560224300_hvag127-B71","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-023-01474-w","article-title":"Large-scale real-life analysis of survival and usage of therapies in multiple myeloma","volume":"16","author":"Lopez-Mu\u00f1oz","year":"2023","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2026092807560224300_hvag127-B72","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1515\/cclm-2024-0306","article-title":"An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients","volume":"62","author":"Wijnands","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"2026092807560224300_hvag127-B73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/CEOR.S498848","article-title":"Using QIP-MS to guide the timing of MRD testing in patients with multiple myeloma: a budget impact analysis from the French payer perspective","volume":"17","author":"Siegfried","year":"2025","journal-title":"Clin Outcomes Res"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/advance-article-pdf\/doi\/10.1093\/clinchem\/hvag127\/71437900\/hvag127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/advance-article-pdf\/doi\/10.1093\/clinchem\/hvag127\/71437900\/hvag127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:56:15Z","timestamp":1790596575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/advance-article\/doi\/10.1093\/clinchem\/hvag127\/8841180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":73,"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvag127","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"hvag127"}}